Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 4/20 | 0.57 |
| ▸ | CTSK | P43235 | 3/20 | 0.57 |
| ▸ | CTSL | P07711 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | IL1RN | P18510 | 1/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24596987 | 0.94 | CTSB (0.59) | CTSBCTSKCTSLCTSSMEN1 | |
| SCHEMBL14595222 | 0.94 | CTSB (0.59) | CTSBCTSKCTSLCTSSMEN1 | |
| SCHEMBL11458944 | 0.89 | CTSB (0.61) | CTSBCTSKCTSLCTSSMEN1 | |
| SCHEMBL18558860 | 0.89 | CTSK (0.57) | CTSBCTSKCTSLCTSSMEN1 | |
| SCHEMBL12516497 | 0.88 | ERAP2 (0.57) | CTSBCTSKCTSLCTSSMEN1 | |
| SCHEMBL2221511 | 0.87 | CTSB (0.56) | CTSBCTSKCTSLCTSSMEN1 | |
| SCHEMBL10087949 | 0.87 | CTSK (0.58) | CTSBCTSKCTSLCTSSMEN1 | |
| SCHEMBL5392148 | 0.87 | CTSB (0.56) | CTSBCTSKCTSLCTSSMEN1 | |
| SCHEMBL5392144 | 0.87 | CTSB (0.56) | CTSBCTSKCTSLCTSSMEN1 | |
| SCHEMBL21074164 | 0.87 | CTSB (0.47) | CTSBCTSKCTSLCTSSMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-9580417-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-02-28 | — | — | US | disclosed |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-01-14 | — | — | US | disclosed |
| US-9107911-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-18 | — | — | US | disclosed |
| WO-2011084850-A1 | PRODRUGS FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISEASE | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | CTSB 2720/4885CTSK 3161/4885CTSL 3126/4885 |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | CYP2D6, CYP2B6, CYP3A4 | CTSB 1269/4885CTSK 1582/4885CTSL 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.